Title:Nanocarrier-based Drug Delivery of Brinzolamide for Ocular Diseases: A Mini-Review
Volume: 15
Issue: 2
Author(s): Rashmi Maurya, Akash Vikal, Preeti Patel, Raj Kumar Narang and Balak Das Kurmi*
Affiliation:
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga-142001, Punjab, India
Keywords:
Brinzolamide, nanocarriers, intraocular pressure, carbonic anhydrase inhibitors, glaucoma, ocular hypertension, ophthalmic drug delivery.
Abstract: Brinzolamide (BRZ) represents a significant advancement in glaucoma treatment as a
topically active carbonic anhydrase inhibitor (CAI). It exhibits selectivity and potent inhibitory activity
for carbonic anhydrase type II isozyme (CA-II), which is crucial in aqueous humor secretion.
With excellent ocular bioavailability and a formulation optimized for physiologic pH, brinzolamide
effectively lowers intraocular pressure by inhibiting CA-II in ciliary processes. Its superior
ocular comfort profile enhances patient compliance. Preclinical evaluations confirm its specific
CA inhibition without notable side effects, and its low systemic absorption minimizes systemic
CA inhibition-related issues. BRZ's prolonged tissue half-life in the eye ensures sustained IOP reduction,
supported by clinical trials demonstrating comparable efficacy with reduced dosing frequency.
Challenges in ocular disease treatment arise from physiological, anatomical, and dynamic
barriers hindering effective drug delivery to the eye. Nanocarriers, such as micelles, nanoparticles,
liposomes, niosomes, and dendrimers, offer promising solutions by improving permeation, targeting
specific sites, and overcoming the limitations of conventional forms. This review explores diverse
nanomedicines, detailing their applications, advantages, and disadvantages in ophthalmic
drug delivery. It also includes recent research findings for a comprehensive overview of the current
landscape.
